Annals of Hematology

, Volume 85, Issue 4, pp 226–232 | Cite as

Grade of bone marrow fibrosis is associated with relevant hematological findings—a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis

Original Article


Controversy continues to exist regarding not only the exact definition and grading of myelofibrosis (MF), but also whether, and to what extent, this feature may be correlated with clinical findings. A retrospective study was performed involving 865 bone marrow (BM) biopsies together with the clinical records from patients with chronic idiopathic myelofibrosis (CIMF). Diagnosis was established according to the World Health Organization criteria, and assessment of MF followed a consensus scoring system that included four grades (MF-0 to MF-3). Histopathological and clinical evaluations were carried out in an independent fashion. Prefibrotic and early CIMF (MF-0/-1) were presented by 565 patients showing borderline to mild anemia and no or slight splenomegaly, but frequently, thrombocytosis exceeding 500×109/l was shown. In 300 patients, manifest reticulin and collagen fibrosis (MF-2/-3) were characterized by marked anemia, gross splenomegaly, peripheral blasts, and normal to decreased platelet and leukocyte counts. The latter cohort was consistent with findings generally in keeping with MF with myeloid metaplasia. Regarding the stepwise evolution of disease, sequential BM examinations showed that in 103 patients, prefibrotic and early CIMF transformed into advanced stages accompanied by correspondingly developing clinical and histomorphological features. Survival analysis (univariate calculation) revealed a significantly more favorable prognosis in prefibrotic vs advanced stages of CIMF. On the other hand, higher classes of MF also exerted a higher clinical risk profile (Lille score). In conclusion, the dynamics of the disease process in CIMF are characterized by evolving MF in the BM and closely associated changes of relevant hematological findings.


Myelofibrosis Grading Clinical features Follow-up Chronic idiopathic myelofibrosis Bone marrow biopsies 


  1. 1.
    Anger B, Seidler R, Haug U, Popp C, Heimpel H (1990) Idiopathic myelofibrosis: a retrospective study of 103 patients. Haematologica 75:228–234PubMedGoogle Scholar
  2. 2.
    Barosi G (1999) Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17:2954–2970PubMedGoogle Scholar
  3. 3.
    Barosi G, Ambrosetti A, Finelli C, Grossi A, Leoni P, Liberato NL, Petti MC, Pogliani E, Ricetti M, Rupoli S, Visani G, Tura S (1999) The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 104:730–737CrossRefPubMedGoogle Scholar
  4. 4.
    Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E (1988) A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 70:397–401PubMedGoogle Scholar
  5. 5.
    Bauermeister DE (1971) Quantitation of bone marrow reticulin — a normal range. Am J Clin Pathol 56:24–31PubMedGoogle Scholar
  6. 6.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMedGoogle Scholar
  7. 7.
    Beckman EN, Brown AW Jr (1990) Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med 114:1241–1243PubMedGoogle Scholar
  8. 8.
    Buhr T, Buesche G, Choritz H, Langer F, Kreipe H (2003) Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 119:152–158CrossRefPubMedGoogle Scholar
  9. 9.
    Buhr T, Georgii A, Choritz H (1993) Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 189:121–132PubMedGoogle Scholar
  10. 10.
    Cervantes F (2005) Modern management of myelofibrosis. Br J Haematol 128:583–592CrossRefPubMedGoogle Scholar
  11. 11.
    Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E (2002) Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 118:786–790CrossRefPubMedGoogle Scholar
  12. 12.
    Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E (1998) Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102:684–690CrossRefPubMedGoogle Scholar
  13. 13.
    Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E (1998) The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol 60:101–105PubMedGoogle Scholar
  14. 14.
    Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, Montserrat E (1997) Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635–640CrossRefPubMedGoogle Scholar
  15. 15.
    Dickstein JI, Vardiman JW (1995) Hematopathologic findings in the myeloproliferative disorders. Semin Oncol 22:355–373PubMedGoogle Scholar
  16. 16.
    Dingli D, Mesa RA, Tefferi A (2004) Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment. Intern Med 43:540–547CrossRefPubMedGoogle Scholar
  17. 17.
    Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013–1018PubMedGoogle Scholar
  18. 18.
    Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V (2004) Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 89:911–919PubMedGoogle Scholar
  19. 19.
    Georgii A, Buesche G, Kreft A (1998) The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 11:721–749PubMedCrossRefGoogle Scholar
  20. 20.
    Georgii A, Buhr T, Buesche G, Kreft A, Choritz H (1996) Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 22[Suppl 1]:15–29PubMedGoogle Scholar
  21. 21.
    Georgii A, Vykoupil KF, Buhr T, Choritz H, Dohler U, Kaloutsi V, Werner M (1990) Chronic myeloproliferative disorders in bone marrow biopsies. Pathol Res Pract 186:3–27PubMedGoogle Scholar
  22. 22.
    Giraudier S, Chagraoui H, Komura E, Barnache S, Blanchet B, LeCouedic JP, Smith DF, Larbret F, Taksin AL, Moreau-Gachelin F, Casadevall N, Tulliez M, Hulin A, Debili N, Vainchenker W (2002) Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood 100:2932–2940CrossRefPubMedGoogle Scholar
  23. 23.
    Goldman JM (2005) A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 352:1744–1746CrossRefPubMedGoogle Scholar
  24. 24.
    Hasselbalch HC (1993) Idiopathic myelofibrosis—an update with particular reference to clinical aspects and prognosis. Int J Clin Lab Res 23:124–138PubMedCrossRefGoogle Scholar
  25. 25.
    Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G (2001) Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) WHO classification of tumours: tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 39–41Google Scholar
  26. 26.
    James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148CrossRefPubMedGoogle Scholar
  27. 27.
    Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162–2168CrossRefPubMedGoogle Scholar
  28. 28.
    Kaushansky K (2005) On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 105:4187–4190CrossRefPubMedGoogle Scholar
  29. 29.
    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790CrossRefPubMedGoogle Scholar
  30. 30.
    Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ (2005) The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol 113:137–143CrossRefPubMedGoogle Scholar
  31. 31.
    Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R (1997) Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 80:708–719CrossRefPubMedGoogle Scholar
  32. 32.
    Laszlo J (1975) Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 12:409–432PubMedGoogle Scholar
  33. 33.
    Le Bousse-Kerdiles MC, Martyre MC (1999) Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 78:437–444CrossRefPubMedGoogle Scholar
  34. 34.
    Le Bousse-Kerdiles MC, Martyre MC (1999) Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia. Springer Semin Immunopathol 21:491–508PubMedGoogle Scholar
  35. 35.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397CrossRefPubMedGoogle Scholar
  36. 36.
    Manoharan A, Horsley R, Pitney WR (1979) The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 43:185–190PubMedGoogle Scholar
  37. 37.
    Martyre MC (2003) Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr Hematol Rep 2:257–263PubMedGoogle Scholar
  38. 38.
    Michiels JJ, Thiele J (2002) Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 76:133–145PubMedCrossRefGoogle Scholar
  39. 39.
    Murphy S (1999) Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 36:9–13PubMedGoogle Scholar
  40. 40.
    Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29–39PubMedGoogle Scholar
  41. 41.
    Pearson TC (1998) Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol 11:695–720PubMedCrossRefGoogle Scholar
  42. 42.
    Pereira A, Cervantes F, Brugues R, Rozman C (1990) Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation. Eur J Haematol 44:95–99PubMedCrossRefGoogle Scholar
  43. 43.
    Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Smith BD, Klingemann HG, Fruchtman S, Hoffman R (2005) Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia. Blood 105:4115–4119CrossRefPubMedGoogle Scholar
  44. 44.
    Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658–2663PubMedCrossRefGoogle Scholar
  45. 45.
    Rupoli S, Da Lio L, Sisti S, Campanati G, Salvi A, Brianzoni MF, D’Amico S, Cinciripini A, Leoni P (1994) Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 68:205–212CrossRefPubMedGoogle Scholar
  46. 46.
    Schmitt A, Drouin A, Masse JM, Guichard J, Shagraoui H, Cramer EM (2002) Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis. Leuk Lymphoma 43:719–724CrossRefPubMedGoogle Scholar
  47. 47.
    Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and the myelodysplastic syndrome. Blood 106:1207–1209CrossRefPubMedGoogle Scholar
  48. 48.
    Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1265CrossRefPubMedGoogle Scholar
  49. 49.
    Thiele J, Chen YS, Kvasnicka HM, Diehl V, Fischer R (1994) Evolution of fibro-osteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosis—a histomorphometric study on sequential trephine biopsies. Leuk Lymphoma 14:163–169PubMedCrossRefGoogle Scholar
  50. 50.
    Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G (2001) Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) WHO classification of tumours: tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 35–38Google Scholar
  51. 51.
    Thiele J, Kvasnicka HM (2003) Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 82:148–152PubMedGoogle Scholar
  52. 52.
    Thiele J, Kvasnicka HM (2003) Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features—a clinicopathological study on 272 patients. Histol Histopathol 18:93–102PubMedGoogle Scholar
  53. 53.
    Thiele J, Kvasnicka HM (2004) Prefibrotic chronic idiopathic myelofibrosis—a diagnostic enigma? Acta Haematol 111:155–159CrossRefPubMedGoogle Scholar
  54. 54.
    Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R (1999) Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)—a clinicopathological study. Leukemia 13:1741–1748CrossRefPubMedGoogle Scholar
  55. 55.
    Thiele J, Kvasnicka HM, Diehl V (2005) Standardization of bone marrow features—does it work in hematopathology for histological discrimination of different disease patterns? Histol Histopathol 20:633–644PubMedGoogle Scholar
  56. 56.
    Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels J (1999) Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 33:207–218PubMedGoogle Scholar
  57. 57.
    Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van der Walt J, Orazi A (2005) European consensus for grading of bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128–1132PubMedGoogle Scholar
  58. 58.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V (2002) Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol 70:283–291CrossRefPubMedGoogle Scholar
  59. 59.
    Thiele J, Kvasnicka HM, Schmitt-Gräff A, Diehl V (2003) Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma 44:549–553CrossRefPubMedGoogle Scholar
  60. 60.
    Thiele J, Kvasnicka HM, Steinberg T, Zankovich R, Fischer R, Diehl V (1992) Survival in primary (idiopathic) osteomyelofibrosis, so-called agnogenic myeloid metaplasia. Leuk Lymphoma 6:389–399CrossRefGoogle Scholar
  61. 61.
    Thiele J, Kvasnicka HM, Werden C, Zankovich R, Diehl V, Fischer R (1996) Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leuk Lymphoma 22:303–317PubMedCrossRefGoogle Scholar
  62. 62.
    Thiele J, Kvasnicka HM, Zankovich R, Diehl V (2000) Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 85:1126–1134PubMedGoogle Scholar
  63. 63.
    Thiele J, Kvasnicka HM, Zankovich R, Diehl V (2002) Early-stage idiopathic (primary) myelofibrosis—current issues of diagnostic features. Leuk Lymphoma 43:1035–1041PubMedGoogle Scholar
  64. 64.
    Thiele J, Zankovich R, Steinberg T, Fischer R, Diehl V (1989) Agnogenic myeloid metaplasia (AMM)—correlation of bone marrow lesions with laboratory data: a longitudinal clinicopathological study on 114 patients. Hematol Oncol 7:327–343PubMedCrossRefGoogle Scholar
  65. 65.
    Vannucchi AM, Bianchi L, Paoletti F, Pancrazzi A, Torre E, Nishikawa M, Zingariello M, Di Baldassarre A, Rana RA, Lorenzini R, Alfani E, Migliaccio G, Migliaccio AR (2005) A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-{beta}1 in the development of myelofibrosis. Blood 105:3493–3501CrossRefPubMedGoogle Scholar
  66. 66.
    Vardiman JW (2003) Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. Semin Diagn Pathol 20:154–179CrossRefPubMedGoogle Scholar
  67. 67.
    Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Latagliata R et al (1990) Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75:4–9PubMedGoogle Scholar
  68. 68.
    Wolf BC, Neiman RS (1985) Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 65:803–809PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Institute for PathologyUniversity of CologneCologneGermany

Personalised recommendations